{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:47:44Z","timestamp":1789469264543,"version":"build-2803163510"},"reference-count":135,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Affimed Therapeutics"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/21645515.2026.2688610","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:02:33Z","timestamp":1781740953000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["NK cell-based immunotherapy"],"prefix":"10.1080","volume":"22","author":[{"given":"Mark Alexander","family":"Forsberg","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yago","family":"Nieto","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/ITT.S163924","article-title":"and the phenomenon of spontaneous regression","volume":"7","author":"Vernon A","year":"2018","unstructured":"Vernon A, William Bradley Coley MD, and the phenomenon of spontaneous regression. Immunotargets Ther. 2018;7:29\u201319.","journal-title":"Immunotargets Ther"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830050208"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10673"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"e_1_3_2_8_1","first-page":"495","article-title":"The application of natural killer cells in cancer immunotherapy","volume":"21","author":"Rezvani K","year":"2015","unstructured":"Rezvani K, Rouce RH. The application of natural killer cells in cancer immunotherapy. Cancer J. 2015;21:495\u2013500.","journal-title":"Cancer J"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.09.013"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom15070935"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrp.2025.102681"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06945-1"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-077438"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.131.4.1789"},{"key":"e_1_3_2_15_1","first-page":"63","article-title":"Diversification and functional specialization of human NK cell subsets","volume":"395","author":"Cichicki F","year":"2016","unstructured":"Cichicki F, Schlums H, Theorell J, Tesi, B, Miller JS, Ljunggren HG, Bryceson YT. Diversification and functional specialization of human NK cell subsets. Curr Top Microbiol Immunol. 2016;395:63\u201394.","journal-title":"Curr Top Microbiol Immunol"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.162.8.4511"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2876"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2013.07.005"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9030753"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/349329a0"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80393-3"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.10.008"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12372"},{"key":"e_1_3_2_24_1","first-page":"553","article-title":"The mature activating natural killer cell immunologic synapse is formed in distinct stages","volume":"4","author":"Orange JS","year":"2003","unstructured":"Orange JS, Harris KE, Andzelm MM, Valter MM, Geha RS, Strominger JL. The mature activating natural killer cell immunologic synapse is formed in distinct stages. Nat Immunol. 2003;4:553\u2013560.","journal-title":"Nat Immunol"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1351"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/319675a0"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.285.5428.727"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.141.10.3478"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/370650a0"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.157.7.2909"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/83416"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.149.11.3495"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.5.3119"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-4035"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00159"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0085-8"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.01.004"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07665"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0813192106"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2021.03.023"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2022.02.015"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119521"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133166"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0632-8"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.879452"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa047"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016200"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030264"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.626098"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1089\/15258160152509145"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00091"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13411"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1089\/152581601750288975"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03350-6"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2974"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0896-z"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.33696\/cancerimmunol.5.074"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011532"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14570"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.11.022"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.260"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2020.10.023"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.03.019"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1159\/000382019"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf2341"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115718"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.626098\/"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03640-8"},{"key":"e_1_3_2_69_1","first-page":"424","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"33","author":"Xie G-Y","year":"2021","unstructured":"Xie G-Y, Zhao Y. CAR-NK cells: a promising cellular immunotherapy for cancer. Curr Opin Oncol. 2021;33:424\u2013431.","journal-title":"Curr Opin Oncol"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add6997"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400330"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2810"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607"},{"issue":"6","key":"e_1_3_2_74_1","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety and efficacy in patients with relapsed or refractory acute myeloid leukemia","volume":"8","author":"Tang X","year":"2018","unstructured":"Tang X, Yang L, Li Z, Nalin AP, Dai H, Xu T, Yin J, You F, Zhu M, Shen W, et al. First-in-man clinical trial of CAR NK-92 cells: safety and efficacy in patients with relapsed or refractory acute myeloid leukemia. Am J Cancer Res. 2018;8(6):1083\u20131089.","journal-title":"Am J Cancer Res"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02785-8"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00940-3"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0096"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-25-0130"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1674376"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep11483"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.12.281"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13255"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(25)00142-5"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02462-0"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-442558"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-614636"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/s44228-022-00023-5"},{"issue":"1","key":"e_1_3_2_88_1","first-page":"S146","article-title":"Completed dose escalation from the first-in-human, phase 1\/2 study of CD123 NK cell engager, SAR443579, in relapsed or refractory acute myeloid leukemia or high risk-myelodysplasia","volume":"8","author":"Garcia S","year":"2024","unstructured":"Garcia S, Bajel A, Maiti A, Desai P, Huls G, Boissel N, Jongen-Lavrencic M, Mantzaris I, De Botton S, de Leeuw D, et al. Completed dose escalation from the first-in-human, phase 1\/2 study of CD123 NK cell engager, SAR443579, in relapsed or refractory acute myeloid leukemia or high risk-myelodysplasia. Hemasphere. 2024;8(S1):S146.","journal-title":"Hemasphere"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2020.0399"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2710"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-168981"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-163561"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.653081"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0649"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1614228"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5c00474"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01114-w"},{"key":"e_1_3_2_98_1","first-page":"4633","article-title":"Single-cell transcriptional profiling of human NK cells reveals distinct tissue-resident and circulating subsets with specialized chemokine receptor programs","volume":"129","author":"Robbins SH","year":"2019","unstructured":"Robbins SH, Sokol H, Kaminski D. Single-cell transcriptional profiling of human NK cells reveals distinct tissue-resident and circulating subsets with specialized chemokine receptor programs. J Clin Invest. 2019;129:4633\u20134645.","journal-title":"J Clin Invest"},{"key":"e_1_3_2_99_1","first-page":"775","article-title":"Immunometabolism of NK cells: metabolic programming governs effector function and anti-tumor activity","volume":"33","author":"Poznanski SM","year":"2021","unstructured":"Poznanski SM, Barra NG, Ashkar AA, Schertzer JD. Immunometabolism of NK cells: metabolic programming governs effector function and anti-tumor activity. Cell Metab. 2021;33:775\u2013788.e5.","journal-title":"Cell Metab"},{"key":"e_1_3_2_100_1","first-page":"38","article-title":"Fc engineering for developing therapeutic bispecific antibodies and novel scaffolds","volume":"8","author":"Liu H","year":"2017","unstructured":"Liu H, Saxena A, Sidhu SS, Wu D. Fc engineering for developing therapeutic bispecific antibodies and novel scaffolds. Front Immunol. 2017;8:38.","journal-title":"Front Immunol"},{"key":"e_1_3_2_101_1","first-page":"1360","article-title":"Afm24: a CD16A-binding EGFR\u00d7CD16A innate cell engager for NK cell\u2013mediated killing of EGFR-expressing tumors","volume":"2","author":"Labrijn AF","year":"2021","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Afm24: a CD16A-binding EGFR\u00d7CD16A innate cell engager for NK cell\u2013mediated killing of EGFR-expressing tumors. Nat Cancer. 2021;2:1360\u20131373.","journal-title":"Nat Cancer"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adn1849"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S492334"},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2710\/"},{"key":"e_1_3_2_105_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2936"},{"key":"e_1_3_2_106_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2024.2378520"},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009934"},{"key":"e_1_3_2_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02003-x"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade0156"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03326-6"},{"key":"e_1_3_2_111_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-154201"},{"key":"e_1_3_2_112_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18444-2"},{"key":"e_1_3_2_113_1","unstructured":"Senti Biosciences. SENTI-202: off-the-shelf logic-gated CAR NK cell therapy in adults with CD33 and\/or FLT3 blood cancers including AML\/MDS. https:\/\/clinicaltrials.gov\/study\/NCT06325748."},{"key":"e_1_3_2_114_1","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122010771"},{"key":"e_1_3_2_115_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106152"},{"key":"e_1_3_2_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.07.001"},{"key":"e_1_3_2_117_1","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aad1884"},{"key":"e_1_3_2_118_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI142116"},{"key":"e_1_3_2_119_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI133353"},{"key":"e_1_3_2_120_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-271874"},{"key":"e_1_3_2_121_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10235"},{"key":"e_1_3_2_122_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI132712"},{"key":"e_1_3_2_123_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1259"},{"key":"e_1_3_2_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2019.03.012"},{"key":"e_1_3_2_125_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6915912"},{"key":"e_1_3_2_126_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4263520"},{"key":"e_1_3_2_127_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.4590"},{"key":"e_1_3_2_128_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5"},{"key":"e_1_3_2_129_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308917"},{"key":"e_1_3_2_130_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04185-6"},{"key":"e_1_3_2_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.04.006"},{"key":"e_1_3_2_132_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adm8186"},{"key":"e_1_3_2_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.07.028"},{"key":"e_1_3_2_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01671-X"},{"key":"e_1_3_2_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.05.038"},{"key":"e_1_3_2_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102282"}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2026.2688610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:02:36Z","timestamp":1781740956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2026.2688610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":135,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/21645515.2026.2688610"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2026.2688610","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2688610"}}